華平股份(300074.SZ):擬以6000萬元購買鄭州新益華醫學20%的股權
格隆匯6月29日丨華平股份(300074.SZ)公佈,公司於2021年6月29日召開第五屆董事會第一次(臨時)會議及第五屆監事會第一次(臨時)會議,分別審議通過了《關於收購新益華部分股權的議案》,同意公司以自有資金6000萬元購買河南園朗企業管理有限公司(“河南園朗”)持有的鄭州新益華醫學科技有限公司(“新益華”或“標的公司”、“目標公司”)20%的股權。
此次交易完成後,加上公司之前持有的新益華36.856%的股權,公司累計將持有新益華56.856%的股權,新益華成為公司的控股子公司,納入公司合併報表範圍。
該協議各方確認,2021年、2022年、2023年標的公司及其子公司鄭州新益華信息科技有限公司合併淨利潤(扣除非經常性損益)將不低於人民幣2594萬元、2853萬元、及3138萬元。上述盈利預測承諾是基於行業發展前景及標的公司近年來經營情況和業務發展規劃等因素所做出的預測承諾,如果標的公司在承諾期內的經營情況未達預期,可能導致業績承諾無法實現,進而影響公司的整體經營業績和盈利水平,敬請投資者注意投資風險。
新益華主要面向醫療、醫保等健康領域,提供軟件諮詢、規劃、設計、研發、實施和運維的信息化整體服務。目前服務於240餘家醫保局、衞健委等管理機構,涉及近億城鄉居民,積累了海量醫療健康數據資源,是國家工業部信息化運行形勢樣本企業、鄭州市百高企業,在行業內享有較高的品牌影響力和市場美譽度。
此次交易是公司積極整合優勢資源,加強在移動醫療發展領域方面的投資布局、打造全方位的智慧醫療生態鏈體系的戰略舉措。此次交易完成後,公司直接持有新益華56.856%的股權,新益華成為公司的控股子公司,納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.